Silicon-Carbide coated Cobalt-Chromium stent with the Abbott Xience PrimeTM stent. The primary endpoint was non-inferiority for in-stent Late Lumen Loss (LLL) at 9 months in de novo coronary artery lesions. Methods: We performed a prospective, multicenter, randomized controlled study (RCT) in 452 subjects (63.4AE10.0 yrs) with symptomatic coronary artery disease due to de novo stenotic lesions in native coronary arteries with a RVD ! 2.25 mm, Ø 4.0 mm and a lesion length 26 mm. Subjects were randomly assigned 2:1 to receive the Osiro SES or the Xience PrimeÔ EES. The primary endpoint of the study is in-stent LLL assessed at 9 months and analyzed according to the intention-to-treat principle. All subjects were enrolled between July 5, 2011-March 23, 2012 and were invited to undergo repeat angiography at 9 months. Clinical follow up visits are performed at 1, 6, 12 months and annually for up to 5 years after the procedure. All angiographic images were analyzed by (R. Waksman, Medstar, Washington DC, USA). All clinical events were adjudicated by 3 independent cardiologists (MD:s). Clinicaltrials.gov no. NCT01356888 Results: Both study groups showed comparable populations in terms of demographics, current risk factors, clinical history and lesion/vessel characteristics. The instent late lumen loss at 9-months was 0.10 AE 0.32 mm for the Osiro compared to 0.11 AE 0.29 mm for the Xience with a p-value of 0.9849. The non-inferiority hypothesis was thereby confirmed with p-value<0.0001. The clinical endpoint of Target Lesion Failure (TLF) at 9 month was 4.8% for the Osiro compared to 5.3% for the Xience with a p-value of 0.9849. Conclusions: In this RCT the Osiro SES with a biodegradable polymer was noninferior to the Xience PrimeÔ EES with a durable polymer for the primary angiographic endpoint of in-stent late loss at 9 months. Clinical event rates were low and comparable with both Osiro and Xience PrimeÔ through 9 months. Results of the clinical event rates at 12 month are now being analyzed and will be presented at the meeting for the first time.
TCT-174
Clinical Outcomes after PCI Treatment of Very Long Coronary Lesions with the XIENCE V Everolimus Eluting Stent (EES): Pooled Analysis from the SPIRIT and XIENCE V USA Prospective Multi-Center Trials James Hermiller Jr, 1 1 St Vincent Heart Center of Indiana, Indianapolis, USA Background: Very long (! 35 mm) coronary lesions are more complex than shorter lesions. Single-stent treatment of very long coronary lesions is limited by maximum stent length, and since stents in the everolimus-eluting cobalt-chromium XIENCE family of coronary stents with lengths > 28 mm have only recently become available, a predetermined planned overlap strategy is most often used for treatment of lesions ! 35 mm in length. There is a substantive body of clinical data for XIENCE V (Abbott Vascular, Santa Clara), but outcomes for very long coronary lesions using Xience V have not previously been reported. Methods: The pooled "XIENCE V Planned Overlap" dataset combines patients treated using XIENCE V with a predetermined planned overlap strategy from six prospective multi-center trials: SPIRIT II, SPIRIT III, SPIRIT IV, SPIRIT V, SPIRIT Small Vessel, and XIENCE V USA. Analyses were performed on subjects with lesions > 24 to < 35 mm in length and ! 35 mm in length. Clinical outcomes evaluated at 1 year included TLF and MACE, all death, cardiac death, all MI, target vessel MI, ID/CI-TLR, and definite and definite/probable stent thrombosis. All endpoint events were adjudicated by independent clinical evaluation committees. Results: There were 482 patients with 500 lesions > 24 to < 35 mm in length, and 323 patients with 328 lesions ! 35 mm in length. The , were similar between groups, except for higher prevalence of hypertension, chronic renal insufficiency and higher body mass index in the diabetic group. Among the 604 SVG lesions treated with DES, the angiographic and procedural characteristics were well matched, except for the higher rate of distal protection device use (32% vs. 29%, p¼0.007) in the diabetic group. The 1-year MACE rate (21% vs. 15%, p¼0.12) and all-cause mortality rate (7.6% vs. 6.7%, p¼0.86) were similar between the two groups. After adjustment for the relevant clinical co-variables, diabetes was not associated with the composite end point.
Conclusions:
Unlike the results seen in de novo lesions, when DES are utilized in PCI of SVG lesions, the presence of diabetes is no loner a discriminator of the short-and long-term outcomes.
TCT-176
High variability of systolic blood pressure predicts long-term adverse outcomes after drug-eluting stent implantation to August 2007 were enrolled. We measured patients' BP in a routine ward environment just before transferring to the cath lab and in the cath lab before arterial puncture (ward-to-cath lab BP) and assessed the differences of systolic and diastolic BP, and heart rate. The subjects were divided into 2 groups according to the differences of ward-to-cath lab systolic BP: high variability group (n¼383) as the absolute difference > 20mmHg and low variability group (n¼424) as the absolute difference 20mmHg. The primary outcome of interest was the composite of death, myocardial infarction (MI), or stroke. Results: In 807 patients (522 males, 60AE10 years), the mean differences of systolic and diastolic BP, and heart rate were 26.5AE18.9 and 11.8AE10.2 mmHg and 10.1AE8.9 beats/min, respectively. During follow-up of 1878AE864 days, composite rate of death, MI, or stroke was higher in the high variability group than the low variability group (10.2% vs. 6.4%; adjusted hazard ratio, 1.96; 95% confidence interval, 1.14-3.38; Cox p¼0.016). The rates of death or MI (7.8% vs. 5.2%, p¼0.09) and stroke (2.3% vs. 1.2%, p¼0.17) were also numerically higher in the high variability group, which did not reach statistical significance. However, there were no significant differences in clinical outcomes for the ward-to-cath lab variability of diastolic BP and heart rate.
Conclusions: This result suggests the variability of ward-to-cath lab systolic BP may contribute to the elevated adverse cardiovascular risk in patients undergoing PCI with DES.
TCT-177
Three Background: The thin-strut, everolimus-eluting, platinum chromium PROMUS Element stent (Boston Scientific, Natick MA) has shown favorable outcomes at 1 and 2 years post-implantation in the treatment of de novo lesions in small vessels (!2.25mm to <2.5mm in baseline diameter) and long lesions (>24 to 34mm in length), but longer-term follow-up has not been previously reported. Methods: PLATINUM SV and LL are prospective, single-arm, multinational studies that enrolled patients with angina pectoris or documented silent ischemia and one de novo native coronary artery target lesion. PLATINUM SV enrolled 94 subjects with baseline vessel diameter !2.25mm to <2.50mm and lesion length 28 mm, and PLATINUM LL enrolled 102 patients with a target lesion >24 to 34mm long with reference diameter !2.50 to 4.25mm. Results: Patients were predominantly male (SV: 72.3%, LL: 62.7%) and approximately one third had diabetes (SV: 42.6%, LL: 30.0%). The mean baseline vessel diameter in SV was 2.04AE0.26 mm, and mean lesion length in LL was 24.38AE8.21 mm. The primary endpoint, 1-year target lesion failure (defined as cardiac death, myocardial infarction related to the target vessel, or ischemia-driven target lesion revascularization), was 2.4% for SV and 3.2% for LL, significantly less than the prespecified performance goals of 21.1% for SV and 19.4% for LL (P<0.001 for each). At 3 years, outcomes for 84 evaluable patients in the SV trial were 4 (4.6%) TLFs, 2 (2.4%) TLRs, 2 (2.3%) cardiac deaths, 1 (1.1%) non-cardiac deaths, and 1 (1.2%) MI, with no ARC definite/probable ST events. Through 2-year follow-up in 95/100 patients in LL, there were 8 (8.8%) TLFs, 5 (5.2%) TLRs, 3 (3.6%) cardiac deaths, 1 (1.0%) non-cardiac death, and no MIs or ARC definite/probable ST. Threeyear results for LL will be available at the time of the meeting. Conclusions: The PROMUS Element stent has demonstrated low target lesion failure and revascularization rates, and acceptable safety outcomes with longer-term followup in patients with small vessels and long lesions. The three-year results from these studies will be available for presentation for the first time at TCT 2013. www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
